← Back
$NBIX All transactions

NEUROCRINE BIOSCIENCES INC

▼ SELL 10b5-1 Plan

$ Value

$761K

Shares

5,000

Price

$152

Filed

Dec 17

Insider

Name

Norwalk Leslie V

Title

CIK

0001533568

Roles

Director

Transaction Details

Transaction Date

2025-12-15

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

7,429

Footnotes

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. | Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.09 to $155.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The option was granted on May 19, 2021 and vested in 12 equal monthly installments beginning June 19, 2021. | The option was granted on May 18, 2022 and vested in 12 equal monthly installments beginning June 18, 2022.

Filing Info

Accession No.

0001533568-25-000007

Form Type

4

Issuer CIK

0000914475

Norwalk Leslie V's History

Date Ticker Type Value
2026-01-21 GMED A $0
2026-01-08 GMED $202K
2025-12-16 NBIX $185K
2025-12-15 NBIX M $764K
2025-12-15 NBIX M $146K
2025-12-15 NBIX $761K
2025-12-15 NBIX M $0
2025-12-15 NBIX M $0
2025-12-12 GMED $355K
2025-11-20 CVS A $126K

Other Insiders at NBIX (90d)

Insider Bought Sold Last
GORMAN KEVIN CHARLES 2026-02-13
Lippoldt Darin
Chief Legal Officer
2026-02-13
Gano Kyle
Chief Executive Officer
2026-02-13
BENEVICH ERIC
Chief Commercial Officer
2026-02-13
ABERNETHY MATT
Chief Financial Officer
2026-03-04
Cooke Julie
Chief Human Resources Officer
2026-02-13
Keswani Sanjay Chandru
Chief Medical Officer
2026-02-13
Onyia Jude
Chief Scientific Officer
2026-02-20
Boyer David W.
Chief Corp. Affairs Officer
2026-02-13
Delaet Ingrid
Chief Regulatory Officer
2026-02-13